Cilostazol increases 3T3-L1 preadipocyte differentiation with improved glucose uptake associated with activation of peroxisome proliferator-activated receptor-γ transcription

Atherosclerosis

Volumn 201, Issue 2, 2008, Pages 258-265

  Park, So Youn ^a   Lee, Jeong Hyun ^a   Kim, Ki Young ^c   Kim, Eun Kyoung ^a   Yun, Sung Ji ^a   Kim, Chi Dae ^a,b   Lee, Won Suk ^a,b   Hong, Ki Whan ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

3T3 L1 fibroblast; C EBP ; Cilostazol; Insulin resistance; PPAR ; Rosiglitazone

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ADIPONECTIN; CCAAT ENHANCER BINDING PROTEIN BETA; CILOSTAZOL; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RESISTIN; ROSIGLITAZONE;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN COS7; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

3T3-L1 CELLS; ANILIDES; ANIMALS; CELL DIFFERENTIATION; CERCOPITHECUS AETHIOPS; COS CELLS; FIBROBLASTS; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPOGLYCEMIC AGENTS; MICE; PHOSPHODIESTERASE INHIBITORS; PPAR GAMMA; TETRAZOLES; THIAZOLIDINEDIONES;

EID: 56649095559     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.02.006     Document Type: Article

References (29)

1. Baron A.D. Insulin resistance and vascular function. J Diabetes Complications 16 (2002) 92-102
2. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 14 (2003) 137-145
3. Vidal-Puig A.J., Considine R.V., Jimenez-Liñan M., et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 99 (1997) 2416-2422
4. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8 (2002) 731-737
5. Olefsky J.M., and Saltiel A.R. PPAR gamma and the treatment of insulin resistance. Trends Endocrinol Metab 11 (2000) 362-368
6. Berger J., Leibowitz M.D., Doebber T.W., et al. Novel peroxisome proliferator-activated receptor (PPAR)γ and PPARδ ligands produce distinct biological effects. J Biol Chem 274 (1999) 6718-6725
7. Lazennec G., Canaple L., Saugy D., and Wahli W. Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 14 (2000) 1962-1975
8. Watanabe M., Inukai K., Katagiri H., et al. Regulation of PPARγ transcriptional activity in 3T3-L1 adipocytes. Biochem Biophys Res Commun 300 (2003) 429-436
9. Shin H.K., Kim Y.K., Kim K.Y., Lee J.H., and Hong K.W. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109 (2004) 1022-1028
10. Park S.Y., Lee J.H., Kim Y.K., et al. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther 312 (2005) 1241-1248
11. Lee J.H., Oh G.T., Park S.Y., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-b formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313 (2005) 502-509
12. Kintscher U., Lyon C., Wakino S., et al. PPARalpha inhibits TGF-beta-induced beta5 integrin transcription in vascular smooth muscle cells by interacting with Smad4. Circ Res 91 (2002) e35-e44
13. Yonemitsu S., Haruo H., Mitsuyo Shintani M., et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 50 (2001) 1093-1101
14. Leesnitzer L.M., Parks D.J., Bledsoe R.K., et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41 (2002) 6640-6650
15. Hallakou S., Doare L., Foufelle F., et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46 (1997) 1393-1399
16. Cornelius P., MacDougald O.A., and Lane M.D. Regulation of adipocyte development. Annu Rev Nutr 14 (1994) 99-129
17. Darlington G.J., Ross S.E., and MacDougald O.A. The role of C/EBP genes in adipocyte differentiation. J Biol Chem 273 (1998) 30057-30060
18. Wu Z., Rosen E.D., Brun R., et al. Cross-regulation of C/EBPa and PPARγ controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 3 (1999) 151-158
19. Hamm J.K., Park B.H., and Farmer S.R. A role for C/EBPbeta in regulating peroxisome proliferator-activated receptor gamma activity during adipogenesis in 3T3-L1 preadipocytes. J Biol Chem 276 (2001) 18464-18471
20. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
21. Nguyen M.T., Satoh H., Favelyukis S., et al. JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3T3-L1 adipocytes. J Biol Chem 280 (2005) 35361-35371
22. Berg A.H., Combs T.P., Du X., Brownlee M., and Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7 (2001) 947-953
23. Combs T.P., Wagner J.A., Berger J., et al. Induction of adipocyte complement-related protein of 30 kilodaltons by PPARγ agonists: a potential mechanism of insulin sensitization. Endocrinology 143 (2002) 998-1007
24. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20 (2000) 1595-1599
25. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001) 2094-2099
26. Kubota N., Terauchi Y., Kubota T., et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281 (2006) 8748-8755
27. Shepherd P.R., and Kahn B.B. Glucose transporters and insulin action. New Engl J Med 341 (1999) 248-257
28. Rosen E.D., Walkey C.J., Puigserver P., and Spiegelman B.M. Transcriptional regulation of adipogenesis. Genes Dev 14 (2000) 1293-1307
29. Rieusset J., Auwerx J., and Vidal H. Regulation of gene expression by activation of the peroxisome proliferator-activated receptor g with rosiglitazone (BRL 49653) in human adipocytes. Biochem Biophys Res Commun 265 (1999) 265-271